NTC srl   Report issue

For profit Phase 3
Founded: Milan Italy (2002)
Status: No NME R&D (2002)

Organization Overview

First Clinical Trial
2017
NCT03365648
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

NTC srl

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cataract (Phase 3)

Inflammation (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 8